



ROMANIA

Confidence Building Measure Return (covering data for 2017)

**Convention on the Prohibition of the Development,
Production and Stockpiling of Bacteriological
(Biological) and Toxin Weapons and on their
Destruction, 10 April 1972**

Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

Measure	Nothing to declare	Nothing new to declare	Year of last declaration if nothing new to declare
A, part 1	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (i)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (ii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (iii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
B	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
C	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
E	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
F	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
G	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

(Please mark the appropriate box(es) for each measure with a tick, and fill in the year of last declaration in the last column where applicable.)

Date: **24 April 2018**

State Party to the Convention: **ROMANIA**

Date of ratification/accession to the Convention: **25 July 1979**

National point of contact: **OSCE, Asymmetrical Risks and Non-Proliferation Directorate**

Ministry of Foreign Affairs

Tel. : +40 21 431 1262, Fax: +40 21 431 1804

E-mail: don@mae.ro

Active promotion of contacts

The Third Review Conference agreed that States parties continue to implement the following:

"Active promotion of contacts between scientists, other experts and facilities engaged in biological research directly related to the Convention, including exchanges and visits for joint research on a mutually agreed basis."

In order to actively promote professional contacts between scientists, joint research projects and other activities aimed at preventing or reducing the occurrence of ambiguities, doubts and suspicions and at improving international cooperation in the field of peaceful bacteriological (biological) activities, the Seventh Review Conference encouraged States parties to share forward looking information, to the extent possible,

- on planned international conferences, seminars, symposia and similar events dealing with biological research directly related to the Convention, and
- on other opportunities for exchange of scientists, joint research or other measures to promote contacts between scientists engaged in biological research directly related to the Convention,

including through the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs.

Confidence-Building Measure "A"

Part 1 Exchange of data on research centres and laboratories

At the Third Review Conference it was agreed that States Parties continue to implement the following:

"Exchange of data, including name, location, scope and general description of activities, on research centres and laboratories that meet very high national or international safety standards established for handling, for permitted purposes, biological materials that pose a high individual and community risk or specialize in permitted biological activities directly related to the Convention."

Modalities

The Third Review Conference agreed on the following, later amended by the Seventh Review Conference:

Data should be provided by States Parties on each facility, within their territory or under their jurisdiction or control anywhere, which has any maximum containment laboratories meeting those criteria for such maximum containment laboratories as specified in the latest edition of the WHO¹ Laboratory Biosafety Manual and/or OIE² Terrestrial Manual or other equivalent guidelines adopted by relevant international organisations, such as those designated as biosafety level 4 (BL4, BSL4 or P4) or equivalent standards.

States Parties that do not possess a facility meeting criteria for such maximum containment should continue to Form A, part 1 (ii).

Form A, part 1 (i)

Exchange of data on research centres and laboratories³

1. Name(s) of facility⁴ _____
2. Responsible public or private
organization or company _____
3. Location and postal address _____

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

¹ World Health Organization

² World Organization for Animal Health

³ The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

⁴ For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

5. Number of maximum containment units⁵ within the research centre and/or laboratory, with an indication of their respective size (m²)

6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

⁵ In accordance with the latest edition of the WHO Laboratory Biosafety Manual, or equivalent.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents⁶ on a State Party's territory:

Biosafety level 3 ⁷	No (under construction)
Biosafety level 2 ⁸ (if applicable)	yes

Any additional relevant information as appropriate:

The facility operating the BSL 2+ containment laboratory is the **Military Medical Research Center**, located in Bucharest, Grigore Cobalcescu street no. 24-28, District 1. The public institution responsible for the reported activity is the Ministry of National Defence, which finances it completely. For daily activities, the specialists work in the Level 2+ laboratory.

⁶ Microorganisms pathogenic to humans and/or animals

⁷ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

⁸ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents⁹ on a State Party's territory:

Biosafety level 3 ¹⁰	no
Biosafety level 2 ¹¹ (if applicable)	yes

Any additional relevant information as appropriate:

The facility operating BSL2 containment laboratories is the research department of the **National Society "Pasteur Institute" SA** (Giulesti street no. 333, District 6, Postal Code 060269, Bucharest). The source of financing of the reported activity is the Ministry of Education, the Pasteur Institute, SC Pasteur – Filipesti Branch SRL and SC Farmavet SA.

The research regards animal viruses, bacteria and parasites: epidemiological and pathological aspects, diagnosis methods, prophylactic / therapeutic bio/medical products (*Escherichia coli*, *Mycoplasma meleagridis*, *M. iowae*, *M. gallisepticum*, *M. synoviae*, *M. hyorhinis*, *M. hyodisenteriae*, *M. floccularis*, *Actinobacillus pleuropneumoniae*, *Haemophilus parasuis*, *Erysipelothrix rhusiopathiae*, *Lawsonia intracellularis*, *Bordetella bronchiseptica*, *Brachispira hyodisenteriae*, *Brachispira pilosicoli*, porcine circovirus 2, porcine respiratory and reproductive syndrome virus, herpes viruses – Marek, Aujeszky, avian laryngotracheitis, canine parvovirus, porcine parvovirus, porcine adenovirus, porcine sapelovirus, porcine A rotavirus, porcine epidemic diarrhea virus, avian rhinotracheitis virus, *Ornithobacterium rhinotracheale*, avian coronavirus, avian leukosis viruses, avipox virus, avian bursitis virus, avian reovirus, avian metapneumovirus, *Toxoplasma gondii*, *Chlamydomyphila abortus*, *Mycoplasma agalactiae*, *Clostridium perfringens*, *Pasteurella multocida* indol-, artemisinin in avian protozoal infections therapy and in vitro quantification by qPCR of the prevalence of Enterobacteriaceae, Enterococcus, Bacteroides, Firmicutes, Bacteroidetes and Eubacteria groups in the poultry intestinal microflora as consequence of in vivo treatment with artemisinin). Diagnostic services for animal breeders and livestock farms are also provided.

The laboratories activities are organized in accordance to ISO 9001:2008 and for some of their methods to ISO 17025:2005 requirements.

⁹ Microorganisms pathogenic to humans and/or animals

¹⁰ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

¹¹ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents¹² on a State Party's territory:

Biosafety level 3 ¹³	yes (not operational)
Biosafety level 2 ¹⁴ (if applicable)	yes

Any additional relevant information as appropriate:

The “Cantacuzino” National Medico-Military Institute for Research and Development (“Cantacuzino” NMMIRD), located in Bucharest, operates several BSL2 containment laboratories (totalling 739.42 sqm) within the Department of Microbiology for Public Health (Viral Respiratory Infections Laboratory, Vaccination Preventable Diseases Laboratory, Vector Borne Diseases Laboratory, Sexually Transmitted Diseases Laboratory, Bacterial Enteric Infections Laboratory, Nosocomial Infections Laboratory, Anaerobical, Fungal and Parasitological Infections Laboratory) and the Department of Research and Development (Innate Immunity Laboratory, Biotechnological Development Laboratory, Cellular and Molecular Immunity, Experimental Microbiology). These laboratories are employed in diagnostic and applied research activities, including test validation, test development and microbiological surveys. The primary objectives of these facilities are to provide a capability allowing Romania to:

- Survey human health status in relation with circulating pathogenic strains (microbiological surveillance);
- Identification of strains of certain micro-organisms not usually found in Romania.

“Cantacuzino” NMMIRD has a BSL3 facility (totalling 175 sqm) within the Department of Microbiology for Public Health, intended for diagnostic and applied research activities. Currently the BSL3 facility is not operational, as there still are several validation procedures to be performed.

“Cantacuzino” NMMIRD has no operational BSL4.

“Cantacuzino” NMMIRD is not involved in any national biological defense research and development programme.

¹² Microorganisms pathogenic to humans and/or animals

¹³ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

¹⁴ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents¹⁵ on a State Party's territory:

Biosafety level 3 ¹⁶	yes
Biosafety level 2 ¹⁷ (if applicable)	yes

Any additional relevant information as appropriate:

Romania's National Sanitary Veterinary and Food Safety Authority operates a BSL3 containment laboratory, component of the **Institute for Diagnosis and Animal Health**, (located in Bucharest, Dr. N. Staicovici street, no. 63, sector 5, zip code 050557; Phone: +40/374.322.013, Fax: . +40/21.411.33.94, e-mail: office@idah.ro , web: www.idah.ro/).

It is used for diagnostic in animal health and welfare; including test validation, and surveys.

Primary objectives are to have a capability allowing Romania to:

- demonstrate its animal health status; and
- demonstrate strains of certain micro-organisms not found in this country.

¹⁵ Microorganisms pathogenic to humans and/or animals

¹⁶ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

¹⁷ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents¹⁸ on a State Party's territory:

Biosafety level 3 ¹⁹	no
Biosafety level 2 ²⁰ (if applicable)	yes

Any additional relevant information as appropriate:

The Institute for Hygiene and Veterinary Public Health, (located in Bucharest, Campul Mosilor street no. 5, postal code 021201) operates several BSL2 containment laboratories. Its source of financing comes only from the National Sanitary Veterinary and Food Safety Authority.

The Institute is the national reference laboratory in the field of animal origin products, food and animal feeding stuffs. Some of the main duties include activities of guidance, proficiency tests, technical co-ordination and control of the county Sanitary Veterinary Food Safety laboratories, sanitary veterinary expertise for animal origin foodstuffs, caring out of results confirmation for laboratory testing, participation in the development of guidelines, instructions and technical details in the field of food safety and participation in the assessment proceedings for the authorization of veterinary microbiology laboratory.

The types of the micro-organisms used in daily activities are mentioned in the following table:

No.	Micro-organism	Reference
1.	<i>Bacillus subtilis</i> subsp. <i>spizizenii</i>	ATCC 6633
2.	<i>Clostridium perfringens</i>	ATCC 13124
3.	<i>Citrobacter freundii</i>	ATCC 43864
4.	<i>Escherichia coli</i>	ATCC 8739
5.	<i>Listeria monocytogenes</i>	ATCC 19111
6.	<i>Listeria innocua</i>	ATCC 33090
7.	<i>Listeria ivanovii</i> subsp. <i>ivanovii</i>	ATCC 19119
8.	<i>Pseudomonas aeruginosa</i>	ATCC 27853
9.	<i>Staphylococcus aureus</i> subsp. <i>aureus</i>	ATCC 6538
10.	<i>Vibrio parahaemolyticus</i>	ATCC 17802
11.	<i>Rhodococcus equi</i>	ATCC 6939

¹⁸ Microorganisms pathogenic to humans and/or animals

¹⁹ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

²⁰ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

12.	Salmonella enterica subsp. enterica serovar enteritidis	ATCC 13076
13.	Salmonella enterica subsp. enterica serovar typhimurium	ATCC 14028
14.	Staphylococcus epidermidis	ATCC 12228
15.	Aspergillus brasiliensis	ATCC 16404
16.	Bacillus cereus	ATCC 11778
17.	Campylobacter jejuni subsp. jejuni	ATCC 33291
18.	Cronobacter muytjensii	ATCC 51329
19.	Enterococcus faecalis	ATCC 29212
20.	Saccharomyces kudriavzevii	ATCC 2601
21.	Yersinia enterocolitica subsp. enterocolitica	ATCC 23715
22.	E. coli O103	ref. EURL VTEC B07
23.	E. coli O111	ref. EURL VTEC A07
24.	E. coli O157	ref. EURL VTEC C07
25.	E. coli O145	ref. EURL VTEC E07
26.	E. coli O26	ref. EURL VTEC D07
27.	E. coli O104:K:H12	ref. SSI H519
28.	E. coli O113:H21	ref. SSI 6182-50
29.	E. coli O55:H-	ref. SSI Su 3912-41
30.	E. coli O121:K-:H10	ref. SSI 39w
31.	E. coli O128ab:H2	ref. SSI Cigleris
32.	E. coli O146:K-:H21	ref. SSI CDC2950-54
33.	E. coli O91:K-:H-	ref. SSI H307B
34.	E. coli O104:H4	ref. SSI D4116
35.	Salmonella Braenderup	ref. SSI H9812
36.	E. coli	ref. EURL VTEC SSI-NN14
37.	E. coli	ref. EURL VTEC EA22
38.	E. coli	ref. EURL VTEC SSI-OO15
39.	E. coli	ref. SSI D2653
40.	E. coli	ref. SSI D3602
41.	E. coli	ref. SSI D3522
42.	E. coli	ref. SSI D3428
43.	E. coli	ref. SSI D3648
44.	E. coli	ref. SSI D3546
45.	E. coli	ref. SSI D3509
46.	E. coli	ref. SSI D3431
47.	E. coli	ref. SSI D4134
48.	Staphylococcus aureus	ref. EURL CPS FRI 137
49.	Staphylococcus aureus	ref. EURL CPS FRI 361
50.	Staphylococcus aureus	ref. EURL CPS A900322
51.	Staphylococcus aureus	ref. EURL CPS FRI S6
52.	Staphylococcus aureus	ref. EURL CPS FRI 326
53.	Listeria monocytogenes	ref. Anses 00EB248LM ref. collection Pasteur Institute Clip74902
54.	Listeria monocytogenes	ref. Anses EURL LM 00EB249LM ref. collection Pasteur

		Institute Clip74903
55.	Listeria monocytogenes	ref. Anses EURL LM 00EB250LM ref. collection Pasteur Institute Clip74904
56.	Listeria monocytogenes	ref. Anses EURL LM 00EB254LM ref. collection Pasteur Institute Clip74908
57.	Listeria monocytogenes	ref. Anses EURL LM 00EB256LM ref. collection Pasteur Institute Clip74910
58.	Norovirus G I	lenticule disc-Certified Reference Material from Public Health England
59.	Norovirus G II	lenticule disc-Certified Reference Material from Public Health England
60.	Hepatitis A virus	lenticule disc-Certified Reference Material from Public Health England
61.	Clostridium botulinum type B	Strain isolated by IHVPH in food
62.	Clostridium botulinum type E	Strain isolated by IHVPH in food

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents²¹ on a State Party's territory:

Biosafety level 3 ²²	no
Biosafety level 2 ²³ (if applicable)	yes

Any additional relevant information as appropriate:

The Institute for Control of Veterinary Biological Products and Medicines (ICVBPM), located in Bucharest, 39 Dudului Street, sector 6, Romania, is a unit with juridical status, functioning as a national reference institute, under the technical subordination of the National Sanitary Veterinary and Food Safety Authority. ICVBPM has competence in the field of veterinary medicinal products, biocides, feed additives, diagnosis sets, other veterinary products (vitamins, mineral supplements and cosmetics).

The main task with relevance on these issues is quality control of veterinary of live and inactivated vaccines for bacterial, viral, parasites:

- live vaccines against distemper, infectious hepatitis, infectious laryngotracheitis, parvovirus and parainfluenza in dogs,
- inactivated vaccine for rabies,
- live and inactivated vaccines for panleucopenia, calicivirus and herpesvirus infection of cats,
- live and inactivated vaccines for IBR, BVD and SRB of bovine,
- rabies live vaccine for oral immunization in foxes,
- live vaccines against Aujeszky virus for pigs,
- live vaccine against myxomatosis and inactivated vaccines for Infectious Rabbit Hemorrhagic Disease,
- live vaccine against infectious bronchitis in poultry, infectious bursitis in poultry (Gumboro disease), Newcastle disease in poultry, inactivated vaccine against the egg drop syndrome, Inactivated vaccine against Newcastle disease and infectious bursitis in poultry,
- vaccine against porcine parvovirus, inactivated,
- vaccine against leptospirosis in dogs and furry animals,
- inactivated vaccine against equine influenza and tetanus,
- inactivated vaccines against parvovirus and swine erysipelas,
- live vaccine against anthrax with B. Anthracis, attenuated strain 1190 R,
- live vaccines for Salmonella in poultry,
- vaccine inactivated against avian Cholerae.

²¹ Microorganisms pathogenic to humans and/or animals

²² In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

²³ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

Quality control of veterinary pharmaceutical products (antimicrobial, anti-inflammatory, antiparasitics, etc.). To perform the quality control of pharmaceutical products is used the microorganisms test as below:

- Staphylococcus aureus ATCC 6538,
- Bacillus subtilis ATCC 6633, NCTC 2589,
- Pseudomonasaeruginosa ATCC 9027,
- Clostridium sporogenes ATCC 11437,
- Candida albicans ATCC 10231,
- Aspergillus Brasiliensis ATCC16404,
- Escherichia coli ATCC 8739, ATCC 10536, ATCC 1133,
- Salmonella enterica subsp. Enterica serovariant typhimurium ATCC 14028,
- Saccharomyces cerevisiae ATCC 2601,
- Micrococcus luteus ATCC 10240, ATCC 9341,
- Bordetella bronchiseptica ATCC 4617,
- Bacillus pumilus NCTC 8241, CIP 76.18,
- Staphylococcus epidermitis NCIMB 8853, CIP 68.21, ATCC 12228,
- Candida tropicalis CIP 1433-83, NCYC 1393,
- Bacillus spizizenii ATCC 4617,
- Streptococcus faecalis 8043.

Diagnostic test kits: for viral, bacterial and parasites disease by following tests: ELISA, immunodiffusion test, complement bond reaction, slow and quick agglutination, immunofluorescent test, immunoperoxidase test.

The laboratory's activities are organized and performed according to ISO 17025:2005 requirements and ISO 9001:2008 requirements.

Part 2 Exchange of information on national biological defence research and development programmes

At the Third Review Conference it was agreed that States Parties are to implement the following:

In the interest of increasing the transparency of national research and development programmes on biological defence, the States Parties will declare whether or not they conduct such programmes. States Parties agreed to provide, annually, detailed information on their biological defence research and development programmes including summaries of the objectives and costs of effort performed by contractors and in other facilities. If no biological defence research and development programme is being conducted, a null report will be provided.

States Parties will make declarations in accordance with the attached forms, which require the following information:

- (1) The objective and summary of the research and development activities under way indicating whether work is conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research;
- (2) Whether contractor or other non-defence facilities are utilized and the total funding provided to that portion of the programme;
- (3) The organizational structure of the programme and its reporting relationships; and
- (4) The following information concerning the defence and other governmental facilities in which the biological defence research and development programme is concentrated;
 - (a) location;
 - (b) the floor areas (sqM) of the facilities including that dedicated to each of BL2, BL3 and BL4 level laboratories;
 - (c) the total number of staff employed, including those contracted full time for more than six months;
 - (d) numbers of staff reported in (c) by the following categories: civilian, military, scientists, technicians, engineers, support and administrative staff;
 - (e) a list of the scientific disciplines of the scientific/engineering staff;
 - (f) the source and funding levels in the following three areas: research, development, and test and evaluation; and
 - (g) the policy regarding publication and a list of publicly-available papers and reports.

Form A, part 2 (i)

National biological defence research and development programmes Declaration

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on

pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes/No

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of each programme.

Form A, part 2 (ii)

National biological defence research and development programmes

Description

1. State the objectives and funding of each programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.
2. State the total funding for each programme and its source.
3. Are aspects of these programmes conducted under contract with industry, academic institutions, or in other non-defence facilities?

Yes/No

4. If yes, what proportion of the total funds for each programme is expended in these contracted or other facilities?
5. Summarize the objectives and research areas of each programme performed by contractors and in other facilities with the funds identified under paragraph 4.
6. Provide a diagram of the organizational structure of each programme and the reporting relationships (include individual facilities participating in the programme).
7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to each national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

Form A, part 2 (iii)

National biological defence research and development programmes

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?

2. Where is it located (include both address and geographical location)?

3. Floor area of laboratory areas by containment level:

BL2 _____ (sqM)

BL3 _____ (sqM)

BL4 _____ (sqM)

Total laboratory floor area _____ (sqM)

4. The organizational structure of each facility.

(i) Total number of personnel _____

(ii) Division of personnel:

Military _____

Civilian _____

(iii) Division of personnel by category:

Scientists _____

Engineers _____

Technicians _____

Administrative and support staff _____

(iv) List the scientific disciplines represented in the scientific/engineering staff.

(v) Are contractor staff working in the facility? If so, provide an approximate number.

(vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

(vii) What are the funding levels for the following programme areas:

Research _____

Development _____

Test and evaluation _____

(viii) Briefly describe the publication policy of the facility:

(ix) Provide a list of publicly-available papers and reports resulting from the work published during the previous 12 months. (To include authors, titles and full references.)

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms²⁴ and/or toxins studied, as well as outdoor studies of biological aerosols.

²⁴ Including viruses and prions.

Confidence-Building Measure "B"

Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins

At the Third Review Conference it was agreed that States Parties continue to implement the following:

Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins, and on all such events that seem to deviate from the normal pattern as regards type, development, place, or time of occurrence. The information provided on events that deviate from the norm will include, as soon as it is available, data on the type of disease, approximate area affected, and number of cases.

The Seventh Review Conference agreed the following:

No universal standards exist for what might constitute a deviation from the normal pattern.

Modalities

The Third Review Conference agreed on the following, later amended by the Seventh Review Conference:

1. Exchange of data on outbreaks that seem to deviate from the normal pattern is considered particularly important in the following cases:

- When the cause of the outbreak cannot be readily determined or the causative agent²⁵ is difficult to diagnose,
- When the disease may be caused by organisms which meet the criteria for risk groups III or IV, according to the classification in the latest edition of the WHO Laboratory Biosafety Manual,
- When the causative agent is exotic to a given geographical region,
- When the disease follows an unusual pattern of development,
- When the disease occurs in the vicinity of research centres and laboratories subject to exchange of data under item A,
- When suspicions arise of the possible occurrence of a new disease.

2. In order to enhance confidence, an initial report of an outbreak of an infectious disease or a similar occurrence that seems to deviate from the normal pattern should be given promptly after cognizance of the outbreak and should be followed up by annual reports. To enable States Parties to follow a standardized procedure, the Conference has agreed that Form B should be used, to the extent information is known and/or applicable, for the exchange of annual information.

3. The declaration of electronic links to national websites or to websites of international, regional or other organizations which provide information on disease outbreaks (notably outbreaks of infectious diseases and similar occurrences caused by

²⁵ It is understood that this may include organisms made pathogenic by molecular biology techniques, such as genetic engineering.

toxins that seem to deviate from the normal pattern) may also satisfy the declaration requirement under Form B.

4. In order to improve international cooperation in the field of peaceful bacteriological (biological) activities and in order to prevent or reduce the occurrence of ambiguities, doubts and suspicions, States Parties are encouraged to invite experts from other States Parties to assist in the handling of an outbreak, and to respond favourably to such invitations, respecting applicable national legislation and relevant international instruments.

Form B

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern²⁶

1. Time of cognizance of the outbreak _____
2. Location and approximate area affected _____
3. Type of disease/intoxication _____
4. Suspected source of disease/intoxication _____
5. Possible causative agent(s) _____
6. Main characteristics of systems _____
7. Detailed symptoms, when applicable _____
 - respiratory _____
 - circulatory _____
 - neurological/behavioural _____
 - intestinal _____
 - dermatological _____
 - nephrological _____
 - other _____
8. Deviation(s) from the normal pattern as regards _____
 - type _____
 - development _____
 - place of occurrence _____
 - time of occurrence _____
 - symptoms _____
 - virulence pattern _____
 - drug resistance pattern _____
 - agent(s) difficult to diagnose _____
 - presence of unusual vectors _____
 - other _____
9. Approximate number of primary cases _____
10. Approximate number of total cases _____
11. Number of deaths _____
12. Development of the outbreak _____
13. Measures taken _____

²⁶ See paragraph 2 of the chapeau to Confidence-Building Measure B.

Confidence-Building Measure "C"

Encouragement of publication of results and promotion of use of knowledge

At the Third Review Conference it was agreed that States parties continue to implement the following:

Encouragement of publication of results of biological research directly related to the Convention, in scientific journals generally available to States parties, as well as promotion of use for permitted purposes of knowledge gained in this research.

Modalities

The Third Review Conference agreed on the following:

1. It is recommended that basic research in biosciences, and particularly that directly related to the Convention should generally be unclassified and that applied research to the extent possible, without infringing on national and commercial interests, should also be unclassified.
2. States parties are encouraged to provide information on their policy as regards publication of results of biological research, indicating, *inter alia*, their policies as regards publication of results of research carried out in research centres and laboratories subject to exchange of information under item A and publication of research on outbreaks of diseases covered by item B, and to provide information on relevant scientific journals and other relevant scientific publications generally available to States parties.
3. The Third Review Conference discussed the question of cooperation and assistance as regards the safe handling of biological material covered by the Convention. It concluded that other international forums were engaged in this field and expressed its support for efforts aimed at enhancing such cooperation.

Romania encourages publication of results of biological research directly related to the Convention provided it is in compliance with good biosecurity practices.

- **Scientific meetings / Scientific communications / posters**

Dinu Horia, Cristina Mich, Marian Culcescu, Virgilia Popa, Daniela Botus, Eduard Caplan, Mihai Danes 2017, Evaluation of pathogenicity of some strains of Salmonella spp. as vaccine candidate on murine model, 18th Scientific Session of the Faculty of Veterinary Medicine of Spiru Haret University, "Veterinary medicine for animal and consumer health", May 11, 2017, Bucharest

Virgilia Popa, Dumitru Militaru, Vasile Cozma, Adriana Gyorke, Beatrice Maria Stirbu Teofanescu, Eduard Caplan, Marian Culcescu, Daniela Botus, Mihai Danes 2017, Resistance to antibiotics and consumption of antibiotics, Quarterly Meeting of the Society of Veterinarians in the Pathology of Avian and Small Animals in Romania, Academy of Agricultural Sciences and Forestry "Gheorghe Ionescu Sisesti", Aula Magna, Bucharest September 27, 2017

Virgilia Popa, Mihai Danes, Victorita Burghilea, Gabriel Paul Duicu, Dumitru Militaru 2017, PASTEUR ROMÂNIA, Past, Present, Future, Anniversary Symposium ASAS 2017

• **Published papers 2017**

Catana N., M. Neculescu, Virgilia Popa, V. Herman, Iulia Bucur 2017, Identification of methicillin resistant Staphylococcus strains by the detection of mec staphylococcal chromosome cassette, Scientific Papers: Veterinary Medicine Timisoara, ISSN:1221-5295, USAMV Timișoara 50 (3):5-10;

http://www.usab-tm.ro/USAMVBT_Revista_ro_1086.html

http://www.usab-tm.ro/utilizatori/medicinaveterinara/volum_1_3.pdf

Catana N., V. Herman, M. Neculescu, Virgilia Popa, Iulia Bucur 2017, Research on the frequency of some staphylococcal species isolated from animals, Scientific Papers: Veterinary Medicine Timisoara, ISSN: 1221-5295, USAMV Timișoara 50 (4):5-11;

http://www.usab-tm.ro/USAMVBT_Revista_ro_1086.html

http://www.usab-tm.ro/utilizatori/medicinaveterinara/volumul_1_4_2017_1.pdf

Fluerasu I., Virgilia Popa, V. Herman, A. Stancu, M. Iovănescu, N. Catana 2017, Serological observation in PRRS syndrome on youth swine, Scientific Papers: Veterinary Medicine Timisoara, ISSN: 1221-5295, USAMV Timișoara 50 (4):173-177;

http://www.usab-tm.ro/USAMVBT_Revista_ro_1086.html

http://www.usab-tm.ro/utilizatori/medicinaveterinara/volumul_1_4_2017_1.pdf

Botus Daniela, G. Ene, M. Culcescu, Virgilia Popa, M. Danes 2017, Evaluation of immune response in sheep after vaccination against contagious agalactia, Scientific Papers: Veterinary Medicine Timisoara, ISSN: 1221-5295, USAMV Timișoara 50 (1):30-38;

http://www.usab-tm.ro/USAMVBT_Revista_ro_1086.html

http://www.usab-tm.ro/utilizatori/medicinaveterinara/volumul_1_1_2017_1.pdf

Viviana Ciuca, Victorita Burghilea, V. V. Safta, Despina Nita, Luciana Paraschiv 2017, Validation studies for the method of determining the protein of "Maleina PPD" based on the Kjel Dahl method, Veterinary Drug 11 (1): 54-60,

http://www.veterinarypharmacon.com/docs/1800-2017_CIUCA_ROM.pdf

Botus Daniela, Marian Culcescu, Virgilia Popa, Mihai Danes 2017, Immuno-enzymatic method (ELISA) for the detection of anti-Mycoplasma agalactiae antibodies, MADR-ASAS. Scientific research offer for technology transfer in agriculture, food and forestry, ISSN 1844-0355

<http://www.asas.ro/wcmqs/academia/publicatii/OfertaCercetarii%202017.pdf>

Popa Virgilia, Daniela Botus, Marian Culcescu, Mihai Danes Virgilia Popa, Daniela Botus, Marian Culcescu, Mihai Danes 2017, Real-time PCR test for detection of Erysipelothrix rhusiopathiae, MADR ASAS. Scientific research offer for technology transfer in agriculture, food and forestry, ISSN 1844-0355

<http://www.asas.ro/wcmqs/academia/publicatii/OfertaCercetarii%202017.pdf>

Popa Virgilia, Daniela Botus, Marian Culcescu, Mihai Danes 2017, Real-time PCR test for detection of Haemophilus parasuis, MADR-ASAS. Scientific research offer for technology transfer in agriculture, food and forestry, ISSN 1844-0355

<http://www.asas.ro/wcmqs/academia/publicatii/OfertaCercetarii%202017.pdf>

Popa Virgilia, Daniela Botus, Marian Culcescu, Eduard Caplan, Mihai Danes 2017, Real-time PCR test for detection of Salmonella spp, MADR-ASAS. Scientific research offer for technology transfer in agriculture, food and forestry, ISSN 1844-0355

<http://www.asas.ro/wcmqs/academia/publicatii/OfertaCercetarii%202017.pdf>

Popa Virgilia, Dumitru Militaru, Beatrice Stirbu, Adriana Gyorke, Anamaria Ioana Pastiu 2017, Real-time PCR methodology for quantification of some bacterial groups in chicken intestinal flora in order to evaluate the effect of some pharmacologically active ingredients, MADR-ASAS. Scientific research offer for technology transfer in agriculture, food and forestry, ISSN 1844-0355

<http://www.asas.ro/wcmqs/academia/publicatii/OfertaCercetarii%202017.pdf>

• **Published papers generated through research and development activities performed within “Cantacuzino” NMMIRD in 2017**

1. D.M. Caplan, M.E. Caplan – Antibiosusceptibility spectrum of *Listeria monocytogenes* strains isolated from Romanian clinical and food samples – International Journal of One Health, 3(1), 40-47, 2017.
2. Usein CR, Ciontea AS, Militaru CM, Condei M, Dinu S, Oprea M, Cristea D, Michelacci V, Scavia G, Zota LC, Zaharia A, Morabito S. - Molecular characterisation of human Shiga toxin-producing *Escherichia coli* O26 strains: results of an outbreak investigation, Romania, February to August 2016. EuroSurveill. 2017 Nov;22(47). FI 7.2
3. Săndulescu O, Bleotu C, Matei L, Streinu-Cercel A, Mihaela Oprea, Drăgulescu EC, Chifiriuc MC, Rafila A, Pirici D, Tălăpan D, Dorobăț OM, Neagu AC, Oțelea D, Berciu I, Ion DA, Codiță I, Calistru PI, Streinu-Cercel A. - Comparative evaluation of aggressiveness traits in staphylococcal strains from severe infections versus nasopharyngeal carriage. Microb Pathog. 2017 Jan;102:45-53 FI 1.888
4. Săndulescu O, Bleotu C, Matei L, Streinu-Cercel A, Oprea M, Drăgulescu E-C, Chifiriuc MC, Rafila A, Pirici D, Tălăpan D, Dorobăț OM, Neagu AC, Oțelea D, Berciu I, Ion DI, Codiță I, Calistru PI, Streinu-Cercel A - Comparative evaluation of aggressiveness traits in staphylococcal strains from severe infections versus nasopharyngeal carriage. Microbial Pathogenesis, 102: 45-53, 2017. ISSN: 0882-4010. IF: 2.009
5. Săvulescu C, Krizova P, Lepoutre A, Mereckiene J, Vestrheim DF, Ciruela P, Ordobas M, Guevara M, McDonald E, Morfeldt E, Kozakova J, Varon E, Cotter S, Winie BA, Munoz-AGmagro C, Garcia L, Castilla J, Smith A, Henriques-Normark B, Celentano LP, Hanquet G, SpIDnet group (Romania: M. Pana, D. Craciun, I. Codița, V. Alexandrescu) - Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study. Lancet Respir. Med. 5(8):648-656, 2017. ISSN: 2213-2600. IF: 15.328
6. Dragomirescu CC, Lixandru B-E, Coldea I-L, Palade AM, Băltoiu M, Dinu S, Cristea VC, Manolescu L, Popa MI - Comparative analysis of different phenotypic and molecular methods used for the taxonomic identification of *Corynebacterium* spp. isolated from clinical samples in Romania – Romanian Biotechnological Letters, 22 (5): 12926 – 12933, 2017

7. Kinross P, Petersen A, Skov R, Van Hauwermeiren E, Pantosti A, Laurent F, Voss A, Kluytmans J, Struelens MJ, Heuer O, Monnet DL, the European human LA-MRSA study group (Romania: Irina Codita) - Livestock-associated meticillin-resistant *Staphylococcus aureus* (MRSA) among human MRSA isolates, European Union/European Economic Area countries, 2013. *Eurosurv.* 22 (44), 2017
8. Codiță I, Pană M. - Diagnosticul de laborator al bolii invazive pneumococice – O performanță în declin? *Rom. Rev. Med. Lab., Suppl.* Vol. 25, 2, S12-S13, 2017. ISSN 1841-6624. IF: 0.143
9. Cristea D, Ciontea SA, Dragomirescu CC, Chifiriuc CM, Andrei MM, Popa A, Codiță I - Interacțiuni microorganism-gazdă implicate în declanșarea proceselor autoimune din artritele reactive. *Infectio.ro*, XII 48 (4): 24-32, 2016
10. Codiță I., Coldea IL, Drăgulescu E-C, Lixandru B-E. - *Staphylococcus aureus* spa types in strains from patients with Staphylococcal Food Poisoning, food chain staff and food, investigated in the 2009-2013 interval at the National Reference Centre for Staphylococcus, Cantacuzino Institute of Research. *One Health International Journal*, Romanian Academy of Medical Sciences, 3(1), 34-39, 2017
11. Coldea I-L, Drăgulescu E-C, Lixandru B-E, Codiță I. - Comparative analysis of antimicrobial resistance in *S.aureus* strains associated with Staphylococcal Food Poisoning investigated at the National Reference Laboratory for Staphylococcus, Cantacuzino National Institute of Research, 2009-2013. *One Health International Journal*, Romanian Academy of Medical Sciences, 3(2), 103-110, 2017
12. Codruța-Romanița Usein, Adriana Simona Ciontea, Cornelia Madalina Militaru, Maria Condei, Sorin Dinu, Mihaela Oprea, Daniela Cristea, Valeria Michelacci, Gaia Scavia, Lavinia Cipriana Zota, Alina Zaharia, Stefano Morabito - Molecular characterisation of human Shiga toxin – producing *Escherichia coli* O:26 strains : results of an outbreak investigation, Romania, february to august 2016. *Eurosurveillance*. European Centre for Disease Prevention and Control (ECDC) 2017 Nov; 22(47). FI 7.2
13. Marina Pana, Mircea Ioan Popa, Georgeta Cristina Oprea, Anamaria Felicia Ilie, Adriana Simona Ciontea, Daniela Cristea, Andrei Popa, Mihaela Melania Andrei, Gabriel Ionescu, Cerasella Cristiana Dragomirescu - Enterococcal urinary tract infections analyzed at “Cantacuzino” National Research Institute” –*Infectio.ro*
14. Adriana Simona Ciontea, Daniela Cristea, Melania Mihaela Andrei, Andrei Popa, Codruta-Romanita Usein - In vitro antimicrobial resistance of urinary *Escherichia coli* isolates from outpatients collected in a laboratory during two years, 2015 and 2017. *Roum Arch Microbiol Immunol*.
15. Daniela Cristea, Adriana Simona Ciontea, Melania Mihaela Andrei, Andrei Popa, Cristina Cerasella Dragomirescu, Mircea Ioan Popa, Irina Codita - Spondyloarthritis and the intestinal microbiome
16. Netta Beer, PhD, Joana Gomes Dias, MMathStat, Robert Whittaker, MSc, Assimoula Economopoulou, PhD, Csaba Ködmön, PhD, Miriam Ramliden, MSc, Lucia Pastore Celentano, PhD, ECDC network members for invasive meningococcal disease - Trends in invasive meningococcal disease following the introduction of meningococcal C conjugate vaccines in Europe, 2004-2014. Sent to *Lancet Infectious Diseases*, 2017
17. HB Bratcher, C Brehony, S. Heuberger, D Pieridou-Bagatzouni, P Krizova, S Hoffmann, M Toropainen, M-K Taha, H Claus, G Tzanakaki, T Erdösi, J Galajeva, A van der Ende, A Skoczynska, M Pana, A Vaculikova, M Paragi, MCJ Maiden, DA Caugant - Establishment of the European meningococcal strain collection genome library (EMSC-GL). *Eurosurveillance* 2017

18. Whittacker R., Dias J.G., Ramliden M., Kodmon K., Economopoulou A., Beer N., Celentano LP., the ECDC network members for invasive meningococcal disease - The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014. *Vaccine* 35 p 2034-2041, 2017.
19. Savulescu C, Krizova P, Lepoutre A, Mereckiene J, Vestrheim DF, Ciruela P, Ordobas M, Guevara M, McDonald E, Morfeldt E, Kozakova J, Varon E, Cotter S, Winje BA, Munoz-Almagro C, Garcia L, Castilla J, Smith A, Henriques-Normark B, Celentano LP, Hanquet G; SpIDnet group. *Czech Republic: P. Krizova, J. Kozakova, M. Maly, H. Sebestova France: A. Lepoutre, C. Levy, E. Varon, R. Cohen, D. Levy-Bruhl Ireland: S. Cotter, J. Mereckiene, MA Fitzgerald, M. Corcoran, R. Cunney, H. Humphreys Norway: D.F. Vestrheim, B.A. Winje, M.A. Riise Bergsaker **Romania:** M. Pana, D. Craciun Scotland, UK: E. McDonald, A. Smith Palmer, A. Smith, B. Denham, B. Jones, J. McMenamin, C. Cameron Sweden: E. Morfeldt, B. Henriques-Normark, J. Darenberg, T. Lepp Spain: R. Cano; Catalonia: P. Ciruela, C. Munoz-Almagro, C. Izquierdo, S. Broner, R. Pallarés; Madrid: M. Ordobas, L. Garcia, A. Arce, J. Carlos Sanz; Navarra: M. Guevara, J. Castilla, C. Ezpeleta, A. Gil-Setas. - Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study. *Lancet Respir Med.* 2017 Mar 27. pii: S2213-2600(17)30110-8. doi: 10.1016/S2213-2600(17)30110-8.
20. Alison Brown, Gianfranco Spiteri, Anastasia Pharris, Otilia Mardh, Judit Takacs, Sexually transmitted infections among young adults in the EU/EEA: 2005-2015. The ECDC HIV/AIDS Surveillance. Sent to Eurosurveillance 2017.
21. Marina Pana “Assessing the impact of vaccination with conjugate vaccines on the epidemiology of invasive pneumococcal disease in Europe”, Lisbon, June 8-9, 2017. (oral communication)
22. Marina Pana, Mircea Ioan Popa, Georgeta Cristina Oprea, Anamaria Felicia Ilie, Simona Adriana Ciontea, Daniela Cristea, Andrei Popa, Mihaela Melania Andrei, Gabriel Ionescu, Cerasella Cristiana Dragomirescu - Enterococcal urinary tract infections analysed at “Cantacuzino” National Research Institute, *Infectio.ro*, 2017.
22. I.M. Neagoe, CM Cretu, L. Lazar - Serological and molecular diagnosis of toxoplasma gondii infection in pregnant women in Romania
23. Purcărea-Ciulacu Valeria, Vladimirescu Alexandru, Petrisor Alexandru, Dumitrescu Gabriela, Saizu Daniela, Savin Elena, Semen Camelia, Mihai Florin, Nicolescu Gabriela - “Endemic presence of West Nile virus in Romania” - The 7th International Congress of the Society for Vector Ecology (SOVE), Palma, Spain, October 2017, Book of abstracts, p 170, ISBN 978-84-697-6086-4.
24. Vladimirescu Alexandru, Dumitrescu Gabriela Victoria, Neculescu Marius, Ionescu Lucia, Popescu Diana, Ordean Viorel, Purcarea-Ciulacu Valeria, Nicolescu Gabriela, Danes Doina, Baraitareanu Stelian, Ciocanau Marius, Ana-Maria Georgescu - “Real time multiplex pcr kit for detection and identification of viral (cchfv and tbev) and bacterial (Francisella turarensis and Borrelia burgdoferi s.l.) Agents transmitted by ticks” - The 7th International Congress of the Society for Vector Ecology (SOVE), Palma, Spain, October 2017, Book of abstracts, p 209, ISBN 978-84-697-6086-4.
25. Purcărea-Ciulacu Valeria, Vladimirescu Alexandru, Petrisor Alexandru, Dumitrescu Gabriela, Saizu Daniela, Savin Elena, Semen Camelia, Mihai Florin, Nicolescu Gabriela - “Endemic presence of West Nile virus in Romania”, International Zoological Congress of “Grigore Antipa” Museum, November 2017, Book of abstracts, p 131, Ed. Interbrand Impex SRL, Bucharest, ISSN: 2457-9769, ISSN-L: 2457-9769

Confidence-Building Measure "D"

(Deleted)

Confidence-Building Measure "E"

Declaration of legislation, regulations and other measures

At the Third Review Conference the States parties agreed to implement the following, later amended by the Seventh Review Conference:

As an indication of the measures which they have taken to implement the Convention, States parties shall declare whether they have legislation, regulations or other measures:

(a) To prohibit and prevent the development, production, stockpiling, acquisition or retention of the agents, toxins, weapons, equipment and means of delivery specified in Article I of the Convention, within their territory or anywhere under their jurisdiction or under their control anywhere;

(b) In relation to the export or import of micro-organisms pathogenic to man, animals and plants or of toxins in accordance with the Convention;

(c) In relation to biosafety and biosecurity.

States parties shall complete the attached form (Form E) and shall be prepared to submit copies of the legislation or regulations, or written details of other measures on request to the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs or to an individual State party. On an annual basis States parties shall indicate, also on the attached form, whether or not there has been any amendment to their legislation, regulations or other measures.

Form E

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures ²⁷	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	Yes	Yes	Yes	No
(b) Exports of micro-organisms ²⁸ and toxins	Yes	Yes	No	Yes

²⁷ Including guidelines.

(c) Imports of micro-organisms ¹¹ and toxins	Yes	No	No	Yes
(d) Biosafety ²⁹ and biosecurity ³⁰	Yes	Yes	Yes	No

Name of legislation, regulations and other measures

No	Specification	No	Year	Topic
1	Council Regulation (EC)	428	2009	Setting up a Community regime for the control of exports, transfer, brokering and transit of dual-use items
2	Commission Delegated Regulation (EU) 2016/1969	2268	2017	Amending Council Regulation (EC) No 428/2009 setting up a Community regime for the control of exports, transfer, brokering and transit of dual-use items
3	Council Regulation (EU) 2015/1861	1861	2015	Modifying Council Regulation (EU) 267/2012 regarding restrictive measures against Iran
4	Government Ordinance	119	2010	Regarding the control regime of dual use operations
5	Law	197	2011	Approving Government Ordinance No 119/2010
6	Government Ordinance	12	2012	Modifying Government Ordinance No 119/2010
7	Law	35	2013	Approving Government Ordinance No 12/2012
8	Order of the Minister of Foreign Affairs	914	2012	Approving the regulation for implementing the provisions of Government Ordinance No 119/2010 regarding the control regime of dual-use operations
9	Order of the Minister of Foreign Affairs	358	2016	Approving the methodological norms for applying the provisions of Council Regulation (EU) 2015/1861 modifying Reg. (EU) 267/2012 regarding restrictive measures against Iran

²⁸ Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

²⁹ In accordance with the latest version of the WHO Laboratory Biosafety Manual or equivalent national or international guidance.

³⁰ In accordance with the latest version of the WHO Laboratory Biosecurity Guidance or equivalent national or international guidance.

Confidence-Building Measure "F"

Declaration of past activities in offensive and/or defensive biological research and development programmes

In the interest of increasing transparency and openness, States parties shall declare whether or not they conducted any offensive and/or defensive biological research and development programmes since 1 January 1946.

If so, States parties shall provide information on such programmes, in accordance with Form F.

Form F

Declaration of past activities in offensive and/or defensive biological research and development programmes

1. Date of entry into force of the Convention for the State Party.

2. Past offensive biological research and development programmes:
 - Yes/No

 - Period(s) of activities

 - Summary of the research and development activities indicating whether work was performed concerning production, test and evaluation, weaponization, stockpiling of biological agents, the destruction programme of such agents and weapons, and other related research.

3. Past defensive biological research and development programmes:
 - Yes/No

 - Period(s) of activities

 - Summary of the research and development activities indicating whether or not work was conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination, and other related research, with location if possible.

Confidence-Building Measure "G"

Declaration of vaccine production facilities

To further increase the transparency of biological research and development related to the Convention and to broaden scientific and technical knowledge as agreed in Article X, each State party will declare all facilities, both governmental and non-governmental, within its territory or under its jurisdiction or control anywhere, producing vaccines licensed by the State party for the protection of humans. Information shall be provided on Form G attached.

Form G

Declaration of vaccine production facilities

1. Name of facility: [The "Cantacuzino" National Medico-Military Institute for Research and Development, Bucharest](#)

2. Location (mailing address): [Splaiul Independentei 103 – 105, 050096, Sector 5, Bucharest, Romania](#)

3. General description of the types of diseases covered:

While the “Cantacuzino” NMMIRD has a production facility and has, in the past, produced several vaccines, the facility is not currently operational. A Trivalent Northern Hemisphere Influenza Vaccine (egg-adapted influenza virus) was manufactured at this facility, as was a monovalent vaccine for the pandemic A/H1N1v strain. A BCG vaccine was also manufactured at the facility.

Form G

Declaration of vaccine production facilities

1. Name of facility: [SC Pasteur – Filiala Filipesti Srl, working point Bucharest](#)

2. Location (mailing address): [333 Giulesti Str., 060269 Bucharest, sector 6, Romania;](#)
[Phone: +40212209909; fax: +40212206915; email: office@pasteur.ro](#)

3. General description of the types of diseases covered: [animal diseases \(viral, bacterial diseases\)](#).
